Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC

Submitted by Anonymous on

BackgroundOsimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). However Abstract Background: Osimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell...

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

Submitted by Anonymous on

SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17...

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches PR Newswire Wed, April 22, 2026 at...

Prognostic Significance of Skin Toxicity in Patients with Ras Wild-Type Metastatic Colorectal Cancer Treated with Anti-Egfr Monoclonal Antibodies

Submitted by Anonymous on

Open AccessArticle Prognostic Significance of Skin Toxicity in Patients with Ras Wild-Type Metastatic Colorectal Cancer Treated with Anti-Egfr Monoclonal Antibodies by Ridvan GonulRidvan Gonul SciProfiles Scilit Preprints.org Google Scholar 1, Oktay BozkurtOktay Bozkurt SciProfiles Scilit Preprints.org Google Scholar 1,*, Gozde...

Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions

Submitted by Anonymous on

The emergence of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) propelled EGFR-mutated patients of non-small cell lung cancer (NSCL 2 Acquired resistance mechanisms2.1 On-target resistance mechanisms Gefitinib and erlotinib, first-generation TKIs, are reversible inhibitors, and second-generation TKIs (represented by...

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy

Submitted by Anonymous on

Open AccessReview Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy by Daniel RosasDaniel Rosas SciProfiles Scilit Preprints.org Google Scholar 1,*, Jay DesaiJay Desai SciProfiles Scilit Preprints.org Google Scholar 2...

Young adults born moderately to extremely preterm have higher eGFR and cystatin C compared to young adults born at term

Submitted by Anonymous on

AbstractBackground Adolescents and adults born preterm are at increased risk for kidney dysfunction, possibly secondary to incomplete nephrogenesis. However, few long-term follow-up studies are available from U.S.-born preterm cohorts. Methods Using the Parkland Hospital Neonatal Intensive Care Unit Registry (Dallas,...

Subscribe to Newsfeed